The Treatment 

The treatment is based on a method of transporting Iodine-131 to tumours where necrosis is present and where it can then destroy any remaining cancer cells.

Necrosis is present in tumours for a variety of reasons, usually following alternative treatment methods which have failed to destroy the tumour mass completely.

Approved necrosis-inducing treatments suitable for combination with Oncocidia include:

·      Radio Frequency Ablation,

·      Microwave Ablation,

·      High Intensity Focussed Ultrasound,

·      Cryotherapy,

·      Ethanol injection.

This makes Oncocidia particularly suitable for use as an adjunct treatment, following these procedures.

A treatment of Iodine-131 labelled hypericin (131I-Hyp) is administered which, being necrosis avid, accumulates in necrotic tissue in the tumour and, through localized and very short range (1-3mm) beta-radiation, attacks any remaining cancer cells.

This approach is intended to improve the treatability of most solid tumours, both primary and metastatic, including some which can be very difficult to treat.

Oncocidia is administered in micro-dose quantities, minimizing chemotoxicities.

Oncocidia thus seeks to build on the success of Iodine-131, currently used to treat thyroid cancer, where it achieves a full remission rate of over 90%.